好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Alpha Rhythm and the Default Mode Network: An EEG-fMRI Study
General Neurology
(-)
021
Authors/Disclosures

PRESENTER
No disclosure on file
Joseph C. Griffis (University of Alabama At Birmingham) No disclosure on file
No disclosure on file
Ging-Yuek R. Hsiung, MD, FAAN (University of British Columbia) Dr. Hsiung has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eisai. Dr. Hsiung has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eli Lilly. The institution of Dr. Hsiung has received research support from CIHR. The institution of Dr. Hsiung has received research support from NIH. The institution of Dr. Hsiung has received research support from Eli Lilly. The institution of Dr. Hsiung has received research support from Biogen.
No disclosure on file
No disclosure on file
No disclosure on file
Jerzy P. Szaflarski, MD, PhD, FAAN (University of Alabama At Birmingham) Dr. Szaflarski has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB Pharma. Dr. Szaflarski has received personal compensation in the range of $500-$4,999 for serving as a Consultant for LivaNova Inc. Dr. Szaflarski has received personal compensation in the range of $500-$4,999 for serving as a Consultant for PureTech Health. Dr. Szaflarski has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Gidley, Sarli & Marusak, LLP. Dr. Szaflarski has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier. Dr. Szaflarski has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Law Firm. Dr. Szaflarski has stock in AdCel Biopharma, LLC. Dr. Szaflarski has stock in iFovea.